Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
ZEVRA THERAPEUTICS, INC. (KMPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Quarterly results
08/14/2023 8-K Investor presentation
Docs: " ",
" "
08/07/2023 8-K Appointed a new director
05/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Transition Agreement, between Zevra Therapeutics, Inc. and Richard W. Pascoe"
04/26/2023 8-K Quarterly results
03/30/2023 8-K Quarterly results
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
03/07/2023 8-K Investor presentation, Quarterly results
Docs: " ",
" "
02/27/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy CELEBRATION, FL, February 27, 2023 – Zevra Therapeutics, Inc. , today announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission in connection with the Company’s 2023 Annual Meeting of Stockholders , which is scheduled to take place on April 25, 2023. Stockholders do not need to take any action with respect to the 2023 Annual Meeting at this time. In its preliminary proxy statement, Zevra announced that the Board has nominated three directors for re-election at the Company’s Annual Meeting — Richard W. Pascoe, David S. Tierney, M.D., and Christopher A. Posner. With the re-election of these serving directors, the Zevra Board will comprise seven highly qualified indiv..."
01/20/2023 8-K Other Events  Interactive Data
01/09/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment to Employment Agreement, between KemPharm, Inc. and Richard W. Pascoe",
"Transition Agreement, as amended, between KemPharm, Inc. and Travis C. Mickle, Ph.D",
"Consulting Agreement"
11/29/2022 8-K Quarterly results
11/18/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
07/01/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
05/31/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/30/2022 8-K Investor presentation, Quarterly results
Docs: " ",
" "
03/21/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: " "
03/16/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: " "
02/22/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: " "
01/19/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: " ",
" "
12/20/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: " "
12/14/2021 8-K Quarterly results
11/10/2021 8-K Investor presentation, Quarterly results
Docs: " ",
" ",
" "
10/19/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market"
08/18/2021 8-K Appointed a new director
Docs: "KemPharm Appoints Tamara A. Seymour to Board of Directors"
08/12/2021 8-K Investor presentation, Quarterly results
Docs: "KemPharm Reports Second Quarter 2021 Financial Results Corporate and Regulatory Highlights",
"Presentation titled "Second Quarter 2021 Results""
07/21/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ by Corium, Inc."
06/24/2021 8-K Submission of Matters to a Vote of Security Holders
06/23/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 23, 2021 KemPharm, Inc. Delaware 001-36913 20-5894398 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747 Registrant's Telephone Number, Including Area Code: 939-3416 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencemen...",
"Certificate of Elimination of Series A Convertible Preferred Stock, filed with the Delaware Secretary of State on June 22, 2021",
"Certificate of Elimination of Series B-1 Convertible Preferred Stock, filed with the Delaware Secretary of State on June 22, 2021",
"Certificate of Elimination of Series B-2 Convertible Preferred Stock, filed with the Delaware Secretary of State on June 22, 2021",
"Form of Inducement Warrant",
"Form of Inducement Letter"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy